Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2018

06.04.2018 | Gastrointestinal Oncology

Value of Preoperative PET-CT in the Prediction of Pathological Stage of Gastric Cancer

verfasst von: Michihiro Kudou, MD, PhD, Toshiyuki Kosuga, MD, PhD, Takeshi Kubota, MD, PhD, Kazuma Okamoto, MD, PhD, Shuhei Komatsu, MD, PhD, Katsutoshi Shoda, MD, PhD, Hirotaka Konishi, MD, PhD, Atsushi Shiozaki, MD, PhD, Hitoshi Fujiwara, MD, PhD, Tomohiro Arita, MD, PhD, Ryo Morimura, MD, PhD, Yasutoshi Murayama, MD, PhD, Yoshiaki Kuriu, MD, PhD, Hisashi Ikoma, MD, PhD, Masayoshi Nakanishi, MD, PhD, Eigo Otsuji, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Preoperative precise staging is essential for the treatment of gastric cancer (GC); however, the diagnostic accuracy of conventional modalities needs to be increased. The present study investigated the clinical value of positron emission tomography-computed tomography (PET-CT) for the staging of GC.

Methods

This was a retrospective study of 117 patients with a clinical diagnosis of advanced GC who underwent PET-CT followed by gastrectomy. The incidence of FDG uptake in the primary tumor or lymph nodes and its relationship with clinicopathological factors, particularly pathological stage (pStage) III/IV, were examined.

Results

FDG uptake in the primary tumor was noted in 83 patients (70.9%). FDG uptake in the lymph nodes was detected in 21 patients (17.9%), and its sensitivity and specificity for lymph node metastasis were 22.7 and 90.5%, respectively. Multiple logistic regression analyses showed that FDG uptake in the primary tumor (odds ratio (OR) 2.764; 95% confidence interval (CI) 1.104–7.459, p = 0.029) and that in the lymph nodes (OR 4.660; 95% CI 1.675–13.84, p = 0.003) were factors independently associated with pStage III/IV. FDG uptake in the primary tumor detected pStage III/IV with higher sensitivity (80.4%) and that in lymph nodes found pStage III/IV with higher specificity (88.7%) than those of upper endoscopy plus CT (60.9 and 67.6%, respectively).

Conclusions

PET-CT appears to be a useful complementary modality in the assessment of pStage III/IV because of the high sensitivity of FDG uptake in the primary tumor and the high specificity of FDG uptake in the lymph nodes.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed
2.
Zurück zum Zitat Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.CrossRefPubMed Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.CrossRefPubMed
3.
Zurück zum Zitat Bang Y-J, Kim Y-W, Yang H-K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21.CrossRefPubMed Bang Y-J, Kim Y-W, Yang H-K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21.CrossRefPubMed
4.
Zurück zum Zitat Kosuga T, Ichikawa D, Otsuji E. Pathologic tumor response to neoadjuvant chemotherapy in gastroesophageal cancer: what does it mean? Transl Gastroenterol Hepatol. 2016;1:75.CrossRefPubMedPubMedCentral Kosuga T, Ichikawa D, Otsuji E. Pathologic tumor response to neoadjuvant chemotherapy in gastroesophageal cancer: what does it mean? Transl Gastroenterol Hepatol. 2016;1:75.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28(35):5210–8.CrossRefPubMedPubMedCentral Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28(35):5210–8.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Boige V, Pignon JP. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. ASCO Annual Meeting. 2007. Boige V, Pignon JP. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. ASCO Annual Meeting. 2007.
7.
Zurück zum Zitat Iwasaki Y, Sasako M, Yamamoto S, et al. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol. 2013;107(7):741–5.CrossRefPubMed Iwasaki Y, Sasako M, Yamamoto S, et al. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol. 2013;107(7):741–5.CrossRefPubMed
8.
Zurück zum Zitat Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol. 2007;25(15):2107–16.CrossRefPubMed Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol. 2007;25(15):2107–16.CrossRefPubMed
9.
Zurück zum Zitat Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer. 2009;12(1):6–22.CrossRefPubMed Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer. 2009;12(1):6–22.CrossRefPubMed
10.
Zurück zum Zitat Serrano OK, Love C, Goldman I, et al. The value of FDG-PET in the staging of gastric adenocarcinoma: a single institution retrospective review. J Surg Oncol. 2016;113(6):640–6.CrossRefPubMed Serrano OK, Love C, Goldman I, et al. The value of FDG-PET in the staging of gastric adenocarcinoma: a single institution retrospective review. J Surg Oncol. 2016;113(6):640–6.CrossRefPubMed
11.
Zurück zum Zitat Li P, Liu Q, Wang C, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer after surgical resection: a systematic review and meta-analysis. Anna Nuclear Med. 2016;30(3):179–87.CrossRef Li P, Liu Q, Wang C, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer after surgical resection: a systematic review and meta-analysis. Anna Nuclear Med. 2016;30(3):179–87.CrossRef
12.
Zurück zum Zitat Kudou M, Shiozaki A, Fujiwara H, et al. Efficacy of PET-CT in the diagnosis and treatment of recurrence after esophageal cancer Surgery. Anticancer Res. 2016;36(10):5473–80.CrossRefPubMed Kudou M, Shiozaki A, Fujiwara H, et al. Efficacy of PET-CT in the diagnosis and treatment of recurrence after esophageal cancer Surgery. Anticancer Res. 2016;36(10):5473–80.CrossRefPubMed
13.
Zurück zum Zitat Pak KH, Yun M, Cheong JH, Hyung WJ, Choi SH, Noh SH. Clinical implication of FDG-PET in advanced gastric cancer with signet ring cell histology. J Surg Oncol. 2011;104(6):566–70.CrossRefPubMed Pak KH, Yun M, Cheong JH, Hyung WJ, Choi SH, Noh SH. Clinical implication of FDG-PET in advanced gastric cancer with signet ring cell histology. J Surg Oncol. 2011;104(6):566–70.CrossRefPubMed
14.
Zurück zum Zitat Shimada H, Okazumi S, Koyama M, Murakami K. Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. Gastric Cancer. 2011;14(1):13–21.CrossRefPubMed Shimada H, Okazumi S, Koyama M, Murakami K. Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. Gastric Cancer. 2011;14(1):13–21.CrossRefPubMed
15.
Zurück zum Zitat Yang DM, Kim HC, Jin W, et al. 64 multidetector-row computed tomography for preoperative evaluation of gastric cancer: histological correlation. J Comp Assist Tomogr. 2007;31(1):98–103.CrossRef Yang DM, Kim HC, Jin W, et al. 64 multidetector-row computed tomography for preoperative evaluation of gastric cancer: histological correlation. J Comp Assist Tomogr. 2007;31(1):98–103.CrossRef
16.
Zurück zum Zitat Hasegawa S, Yoshikawa T, Shirai J, et al. A prospective validation study to diagnose serosal invasion and nodal metastases of gastric cancer by multidetector-row CT. Ann Surg Oncol. 2013;20(6):2016–22.CrossRefPubMed Hasegawa S, Yoshikawa T, Shirai J, et al. A prospective validation study to diagnose serosal invasion and nodal metastases of gastric cancer by multidetector-row CT. Ann Surg Oncol. 2013;20(6):2016–22.CrossRefPubMed
17.
Zurück zum Zitat Japanese Gastric Cancer A. Japanese classification of gastric carcinoma: 3rd English edn. Gastric Cancer. 2011;14(2):101–12. Japanese Gastric Cancer A. Japanese classification of gastric carcinoma: 3rd English edn. Gastric Cancer. 2011;14(2):101–12.
18.
Zurück zum Zitat Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14(2):113–23.CrossRef Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14(2):113–23.CrossRef
19.
Zurück zum Zitat Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19.CrossRef Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19.CrossRef
20.
Zurück zum Zitat Kim HW, Won KS, Song BI, Kang YN. Correlation of primary tumor FDG uptake with histopathologic features of advanced gastric cancer. Nucl Med Mol Imaging. 2015;49(2):135–42.CrossRefPubMedPubMedCentral Kim HW, Won KS, Song BI, Kang YN. Correlation of primary tumor FDG uptake with histopathologic features of advanced gastric cancer. Nucl Med Mol Imaging. 2015;49(2):135–42.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Kaneko Y, Murray WK, Link E, Hicks RJ, Duong C. Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer. J Nucl Med. 2015;56(4):523–9.CrossRefPubMed Kaneko Y, Murray WK, Link E, Hicks RJ, Duong C. Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer. J Nucl Med. 2015;56(4):523–9.CrossRefPubMed
22.
Zurück zum Zitat Fukagawa T, Katai H, Mizusawa J, et al. A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer. 2018;21(1):68–73.CrossRefPubMed Fukagawa T, Katai H, Mizusawa J, et al. A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer. 2018;21(1):68–73.CrossRefPubMed
23.
Zurück zum Zitat Mocellin S, Pasquali S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. The Cochrane database of systematic reviews. 2015(2):Cd009944. Mocellin S, Pasquali S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. The Cochrane database of systematic reviews. 2015(2):Cd009944.
24.
Zurück zum Zitat Grabinska K, Pelak M, Wydmanski J, Tukiendorf A, d’Amico A. Prognostic value and clinical correlations of 18-fluorodeoxyglucose metabolism quantifiers in gastric cancer. World J Gastroenterol. 2015;21(19):5901–9.CrossRefPubMedPubMedCentral Grabinska K, Pelak M, Wydmanski J, Tukiendorf A, d’Amico A. Prognostic value and clinical correlations of 18-fluorodeoxyglucose metabolism quantifiers in gastric cancer. World J Gastroenterol. 2015;21(19):5901–9.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Park JC, Lee JH, Cheoi K, et al. Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor. Eur J Nucl Med Mol Imaging. 2012;39(7):1107–16.CrossRefPubMed Park JC, Lee JH, Cheoi K, et al. Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor. Eur J Nucl Med Mol Imaging. 2012;39(7):1107–16.CrossRefPubMed
Metadaten
Titel
Value of Preoperative PET-CT in the Prediction of Pathological Stage of Gastric Cancer
verfasst von
Michihiro Kudou, MD, PhD
Toshiyuki Kosuga, MD, PhD
Takeshi Kubota, MD, PhD
Kazuma Okamoto, MD, PhD
Shuhei Komatsu, MD, PhD
Katsutoshi Shoda, MD, PhD
Hirotaka Konishi, MD, PhD
Atsushi Shiozaki, MD, PhD
Hitoshi Fujiwara, MD, PhD
Tomohiro Arita, MD, PhD
Ryo Morimura, MD, PhD
Yasutoshi Murayama, MD, PhD
Yoshiaki Kuriu, MD, PhD
Hisashi Ikoma, MD, PhD
Masayoshi Nakanishi, MD, PhD
Eigo Otsuji, MD, PhD
Publikationsdatum
06.04.2018
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6455-0

Weitere Artikel der Ausgabe 6/2018

Annals of Surgical Oncology 6/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.